Decrease of peripheral blood lymphocyte count predicts response to neoadjuvant chemotherapy in breast cancer patients.

Breast neoplasms Neoadjuvant chemotherapy Pathological complete remission Peripheral blood lymphocytes

Journal

Korean journal of clinical oncology

ISSN: 2288-4084

Titre abrégé: Korean J Clin Oncol

Pays: Korea (South)

ID NLM: 9918521386106676

Informations de publication

Date de publication:
Dec 2020

Historique:

received: 21 09 2020

revised: 12 11 2020

accepted: 02 12 2020

entrez: 22 3 2023

pubmed: 1 12 2020

medline: 1 12 2020

Statut: ppublish

Résumé

Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) holds promise as a significant prognostic factor to predict NAC response in breast cancer patients. The absolute peripheral blood lymphocyte (PBL) count has been suggested as an independent predictor of response to NAC. The current study evaluated the relationship between pCR and the change of PBL count in patients treated with NAC. A total of 61 patients with histologically confirmed breast cancer treated with NAC followed by mastectomy between January 2010 and December 2019 were analyzed retrospectively. Correlational analyses confirmed a statistically significant relationship between PBL count and pCR. Following conformational correlational analyses, patients were divided into two groups according to cutoff values using the receiver operating characteristics curve and a logistic regression was conducted to determine the optimal conditions for achieving pCR. A total of 14 patients (22.9%) achieved pCR. Most PBL counts decreased after NAC relevant to pCR. Logistic regression analysis revealed that a small decrease of PBL was associated with pCR (P=0.028). The cutoff value of PBL decrease was 755×10 The decrease of PBL is significantly associated with pCR. Our data support that the decrease of PBL after NAC may be useful factors in predicting the response to NAC in breast cancer patients.

Identifiants

DOI: 10.14216/kjco.20013 PMID: 36945713 PMC: PMC9942727

pubmed: 36945713

doi: 10.14216/kjco.20013

pii: kjco-16-2-79

pmc: PMC9942727

doi:

Types de publication

Journal Article

Langues

eng

Pagination

79-88

Informations de copyright

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

Références

Pancreas. 2006 Jan;32(1):22-8

pubmed: 16340740

Med Hypotheses. 2008 Nov;71(5):802-4

pubmed: 18691831

Breast. 2014 Oct;23(5):526-37

pubmed: 25034931

Breast. 2012 Aug;21(4):468-74

pubmed: 22119767

J Clin Oncol. 2015 Oct 1;33(28):3199-212

pubmed: 26169616

J Clin Invest. 2008 Jun;118(6):1991-2001

pubmed: 18523649

Eur J Cancer. 2011 Sep;47(14):2084-90

pubmed: 21737257

N Engl J Med. 1992 Jul 2;327(1):28-35

pubmed: 1375975

Breast. 2019 Apr;44:33-38

pubmed: 30611095

Br J Cancer. 1996 Mar;73(6):758-62

pubmed: 8611376

Cancer Immunol Immunother. 2008 Nov;57(11):1579-87

pubmed: 18369619

J Clin Oncol. 2011 Sep 1;29(25):3351-7

pubmed: 21788566

Clin Cancer Res. 2005 Aug 15;11(16):5678-85

pubmed: 16115903

Cancer. 2006 May 15;106(10):2258-66

pubmed: 16575919

PLoS One. 2016 Jul 29;11(7):e0153459

pubmed: 27472762

Ann Surg Oncol. 2011 Oct;18(11):3160-3

pubmed: 21947594

Breast Cancer Res. 2007;9(4):212

pubmed: 17705880

J Clin Oncol. 2003 Dec 15;21(24):4540-5

pubmed: 14673041

Sci Rep. 2018 Apr 18;8(1):6223

pubmed: 29670115

Ann Surg Oncol. 2012 Jan;19(1):253-8

pubmed: 21725686

Breast Cancer Res. 2017 Jan 5;19(1):2

pubmed: 28057046

Radiat Oncol. 2010 Jun 03;5:47

pubmed: 20525293

Oncotarget. 2016 Jul 12;7(28):44288-44298

pubmed: 27329588